
https://www.science.org/content/blog-post/mix-em-all-together
# Mix ’Em All Together (July 2012)

## 1. SUMMARY  
The post is a brief blog entry announcing that science‑fiction writer **Charles Stross** has published a short story titled **“A Tall Tail”** (on Tor.com). The author of the blog links the story to his own “Things I Won’t Work With” series and to John Clark’s book *Ignition*, suggesting that the narrative explores the idea of **mixing together chemical or biological compounds in unexpected ways**. The post’s purpose is mainly to point readers to the story and to note the playful, speculative nature of the premise.

## 2. HISTORY  
- **The story itself** remained a piece of speculative fiction. It was published on Tor.com in July 2012 and has been archived there; it has not been adapted into a film, TV episode, or commercial product.  
- **No direct biotech impact** can be traced to the story. There were no drugs, platforms, or companies that cited “A Tall Tail” as an inspiration for research or development.  
- **Broader synthetic‑biology trends** have advanced dramatically since 2012 (CRISPR‑Cas9 becoming a routine tool, the rise of cell‑therapy pipelines, and the growth of modular DNA‑assembly standards). These advances align loosely with the story’s theme of “mixing compounds,” but the connection is conceptual rather than causal.  
- **Charles Stross** continued to publish novels and short fiction, many of which incorporate biotech motifs, but none have been reported to influence regulatory policy or industry roadmaps.  
- **The blog’s “Things I Won’t Work With” series** continued for a few more years, remaining a niche commentary for a small audience; it did not evolve into a widely cited thought‑leadership platform.

## 3. PREDICTIONS  
The blog entry does not contain explicit, numbered predictions. Implicitly, it suggests that **future biotechnologists might experiment with unconventional compound combinations**. Evaluating that implication:

- **Modular synthetic biology** has indeed become a mainstream engineering approach (e.g., BioBricks, iGEM standards). Researchers routinely assemble genetic parts from disparate origins, which mirrors the “mix‑and‑match” vibe of the story.  
- **Commercial drug discovery** has not moved toward the kind of reckless, ad‑hoc mixing of unrelated small molecules that the story dramatizes; modern pipelines remain highly target‑focused and safety‑driven.  
- **Regulatory frameworks** have tightened around novel combination products (e.g., drug‑device combos), reflecting caution rather than the free‑wheeling experimentation implied by the narrative.  

Overall, the story’s speculative vision anticipated a cultural fascination with “mixing everything together,” a theme that has indeed become a popular trope in biotech fiction, but the concrete industry trajectory has been more measured.

## 4. INTEREST  
**Rating: 4/10** – The post is a niche announcement of a short story; it is interesting to fans of speculative biotech fiction but has had no measurable influence on the real biotechnology sector.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120723-mix-em-all-together.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_